search icon
  • What's New in Practice Management & Payment

    MIPS Reporting Deadlines Fast Approaching: 10 Things to Do and Know

    CMS MIPS Data Submission Portal Now Available

    2016 Physician Compare Data Now Available

    AMA Releases an Interactive Web-based Tool for MIPS

    CMS Releases 2018 Medicare Physician Fee Schedule Proposed Rule

  • 2018 ID Week logo final

The HIV Medicine Association is an organization of medical professionals who practice HIV medicine. We represent the interests of our patients by promoting quality in HIV care and by advocating for policies that ensure a comprehensive and humane response to the AIDS pandemic informed by science and social justice.

  • News from IDSA and Journals

    2/15/2018

    New IDSA, SHEA C. diff Guidelines

    Read More >>

    New diagnostic methods and treatments – including fecal transplantation – will help improve the care of patients with Clostridium difficile(C. diff.), a deadly bacterial infection that can occur after antibiotic use, according to updated guidelines released by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) and published in the journal Clinical Infectious Diseases.

  • CDC and FDA Alerts

    1/19/2018 11:25:10 AM

    Levofloxacin in 5 Percent Dextrose 250mg/50mL by AuroMedics: Recall - Presence of Visible Particulate Matter

    AuroMedics Pharma LLC is voluntarily recalling one lot of Levofloxacin in 5% Dextrose Injection 250mg/50mL in a Single-Use flexible container NDC 55150-243-46, Lot CLF160003, Expiry date May 2018, to the hospital level.

    1/8/2018 4:51:03 PM

    Early Season Influenza A(H3N2) Activity and Treatment of Patients with Influenza Antiviral Medications

    The Centers for Disease Control and Prevention (CDC) is providing: 1) a notice about increased influenza A(H3N2) activity and its clinical implications; 2) a summary of influenza antiviral drug treatment recommendations; 3) an update about approved treatment drugs and supply this season; and 4) background information for patients about influenza treatment.

    12/28/2017 4:54:06 PM

    CDC Investigating Multistate Outbreak of E. coli O157:H7 Infections

    CDC, several states, and the U.S. Food and Drug Administration are investigating a multistate outbreak of Shiga toxin-producing E. coli O157:H7 infections (STEC O157:H7) in 13 states. Seventeen illnesses have been reported from California (3), Connecticut (2), Illinois (1), Indiana (1), Michigan (1), Nebraska (1), New Hampshire (2), New York (1), Ohio (1), Pennsylvania (1), Virginia (1), Vermont (1) and Washington (1).

    12/28/2017 2:09:50 PM

    Seasonal Influenza A(H3N2) Activity and Antiviral Treatment of Patients with Influenza

    The Centers for Disease Control and Prevention (CDC) is providing: 1) a notice about increased influenza A(H3N2) activity and its clinical implications; 2) a summary of influenza antiviral drug treatment recommendations; 3) an update about approved treatment drugs and supply this season; and 4) background information for patients about influenza treatment.

    12/19/2017 2:23:09 PM

    Investigation of Salmonella Infection Linked to Rattlesnake Pills

    The Centers for Disease Control and Prevention and the Kansas Department of Health and Environment have linked one person’s Salmonella Oranienburg infection to taking rattlesnake pills.

    12/19/2017 2:15:46 PM

    FDA issues final rule on OTC health care antiseptic hand washes and rubs

    The FDA has finalized a rule first proposed in 2015 that finds that triclosan and 23 other active ingredients are not generally recognized as safe and effective (GRASE) for use in over-the-counter (OTC) health care antiseptic products – including health care personnel hand washes and rubs, surgical hand scrubs and rubs, and patient antiseptic skin preparations — because no additional safety and effectiveness data were provided to the FDA to support monograph conditions for these 24 active ingredients.

    12/1/2017 1:11:40 PM

    Merck Receives FDA Approval for ISENTRESS

    Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ISENTRESS® (raltegravir), the company’s integrase inhibitor, for use in combination with other antiretroviral agents, for the treatment of HIV-1 in neonates – newborn patients from birth to four weeks of age – weighing at least 2 kg.

    11/27/2017 1:37:12 PM

    People in Four States May Be Drinking Contaminated Raw Milk

    The Centers for Disease Control and Prevention is warning people in the states of Connecticut, New Jersey, New York and Rhode Island, who might have consumed contaminated raw milk and milk products to visit their doctor. 

| IDSA | Contact Us

© Copyright HIVMA 2017 HIV Medicine Association

Full Site Mobile Site